About Protein mono-ADP-ribosyltransferase PARP14
Protein mono-ADP-ribosyltransferase PARP14 (PARP14) is a protein
from Homo sapiens identified by UniProt accession
Q460N5, 1801 residues long.
MolForge cross-references it against 0 known binders and
186 disease associations.
Target properties
| Protein name | Protein mono-ADP-ribosyltransferase PARP14 |
|---|
| UniProt accession | Q460N5 |
|---|
| Gene | PARP14 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 1801 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Approved drugs hitting this target (3)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (186)
Diseases linked to this target (Open Targets).
- COVID-19 · score 0.37
- severe acute respiratory syndrome · score 0.37
- neurodegenerative disease · score 0.37
- acoustic startle blink response measurement · score 0.21
- mean platelet volume · score 0.19
- sex hormone-binding globulin measurement · score 0.12
- serum albumin measurement · score 0.09
- neoplasm · score 0.08
- hepatocellular carcinoma · score 0.08
- Spinal cord injury · score 0.07
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q460N5-F1 | alphafold | PREDICTED | 81.68 | — |
Amino-acid sequence (1801 residues)
MAVPGSFPLL VEGSWGPDPP KNLNTKLQMY FQSPKRSGGG ECEVRQDPRS PSRFLVFFYP EDVRQKVLER KNHELVWQGK GTFKLTVQLP ATPDEIDHVF EEELLTKESK TKEDVKEPDV SEELDTKLPL DGGLDKMEDI PEECENISSL VAFENLKANV TDIMLILLVE NISGLSNDDF QVEIIRDFDV AVVTFQKHID TIRFVDDCTK HHSIKQLQLS PRLLEVTNTI RVENLPPGAD DYSLKLFFEN PYNGGGRVAN VEYFPEESSA LIEFFDRKVL DTIMATKLDF NKMPLSVFPY YASLGTALYG KEKPLIKLPA PFEESLDLPL WKFLQKKNHL IEEINDEMRR CHCELTWSQL SGKVTIRPAA TLVNEGRPRI KTWQADTSTT LSSIRSKYKV NPIKVDPTMW DTIKNDVKDD RILIEFDTLK EMVILAGKSE DVQSIEVQVR ELIESTTQKI KREEQSLKEK MIISPGRYFL LCHSSLLDHL LTECPEIEIC YDRVTQHLCL KGPSADVYKA KCEIQEKVYT MAQKNIQVSP EIFQFLQQVN WKEFSKCLFI AQKILALYEL EGTTVLLTSC SSEALLEAEK QMLSALNYKR IEVENKEVLH GKKWKGLTHN LLKKQNSSPN TVIINELTSE TTAEVIITGC VKEVNETYKL LFNFVEQNMK IERLVEVKPS LVIDYLKTEK KLFWPKIKKV NVQVSFNPEN KQKGILLTGS KTEVLKAVDI VKQVWDSVCV KSVHTDKPGA KQFFQDKARF YQSEIKRLFG CYIELQENEV MKEGGSPAGQ KCFSRTVLAP GVVLIVQQGD LARLPVDVVV NASNEDLKHY GGLAAALSKA AGPELQADCD QIVKREGRLL PGNATISKAG KLPYHHVIHA VGPRWSGYEA PRCVYLLRRA VQLSLCLAEK YKYRSIAIPA ISSGVFGFPL GRCVETIVSA IKENFQFKKD GHCLKEIYLV DVSEKTVEAF AEAVKTVFKA TLPDTAAPPG LPPAAAGPGK TSWEKGSLVS PGGLQMLLVK EGVQNAKTDV VVNSVPLDLV LSRGPLSKSL LEKAGPELQE ELDTVGQGVA VSMGTVLKTS SWNLDCRYVL HVVAPEWRNG STSSLKIMED IIRECMEITE SLSLKSIAFP AIGTGNLGFP KNIFAELIIS EVFKFSSKNQ LKTLQEVHFL LHPSDHENIQ AFSDEFARRA NGNLVSDKIP KAKDTQGFYG TVSSPDSGVY EMKIGSIIFQ VASGDITKEE ADVIVNSTSN SFNLKAGVSK AILECAGQNV ERECSQQAQQ RKNDYIITGG GFLRCKNIIH VIGGNDVKSS VSSVLQECEK KNYSSICLPA IGTGNAKQHP DKVAEAIIDA IEDFVQKGSA QSVKKVKVVI FLPQVLDVFY ANMKKREGTQ LSSQQSVMSK LASFLGFSKQ SPQKKNHLVL EKKTESATFR VCGENVTCVE YAISWLQDLI EKEQCPYTSE DECIKDFDEK EYQELNELQK KLNINISLDH KRPLIKVLGI SRDVMQARDE IEAMIKRVRL AKEQESRADC ISEFIEWQYN DNNTSHCFNK MTNLKLEDAR REKKKTVDVK INHRHYTVNL NTYTATDTKG HSLSVQRLTK SKVDIPAHWS DMKQQNFCVV ELLPSDPEYN TVASKFNQTC SHFRIEKIER IQNPDLWNSY QAKKKTMDAK NGQTMNEKQL FHGTDAGSVP HVNRNGFNRS YAGKNAVAYG KGTYFAVNAN YSANDTYSRP DANGRKHVYY VRVLTGIYTH GNHSLIVPPS KNPQNPTDLY DTVTDNVHHP SLFVAFYDYQ AYPEYLITFR K
Explore Protein mono-ADP-ribosyltransferase PARP14 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets